We found that overall, adjuvant TACE can improve the tumor-free survival rate at 1 year, showing a preventive effect on early tumor recurrence, and that there was an increasing trend for 2- and 3-year tumor-free survival rates in the adjuvant TACE group.
← all excerpts
Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
1
—
—